Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone marrow samples will be collected and cryopreserved from MDS patients before transplantation and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected before transplant to study genomic and transcriptomic changes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Diagnosis of MDS according to 2016 WHO criteria

• Aged 18y or older

• Patients who will receive allogeneic stem cell transplantation (HSCT)

• Signed written informed consent according to ICH/EU/GCP and national local laws

Locations
Other Locations
Italy
Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
RECRUITING
Bari
Unità di Ricerca e di Malattie del sangue - Ematologia S. Luca Vecchio
RECRUITING
Florence
AOU San Martino-IST-Ematologia 1
RECRUITING
Genova
Sezione di Ematologia - Ospedale S.Maria della Misericordia
RECRUITING
Perugia
Dip. di Medicina Trasl. E di Precisione - U.O.C. Ematologia
RECRUITING
Roma
Policlinico Tor Vergata
RECRUITING
Roma
Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia
RECRUITING
Rozzano
Contact Information
Primary
Paola Fazi
p.fazi@gimema.it
0670390528
Backup
Enrico Crea
e.crea@gimema.it
0670390514
Time Frame
Start Date: 2021-02-12
Estimated Completion Date: 2025-03
Participants
Target number of participants: 38
Treatments
Other: Biological evaluation
evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.
Sponsors
Leads: Gruppo Italiano Malattie EMatologiche dell'Adulto

This content was sourced from clinicaltrials.gov